Strensiq asfotase alfa regulatory update

The European Commission approved an MAA from Alexion for Strensiq asfotase alfa for long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia (HPP) to treat the bone manifestations of the disease. The company plans to launch Strensiq in October, initially only in Germany. HPP is an inherited metabolic disease characterized by defective bone mineralization. ...